HFpEF Outcomes Improve With Semaglutide in T2DM and Obesity
Mar 7, 2025 · HFpEF outcomes were improved with semaglutide, compared with placebo, among patients with obesity-related HFpEF and type 2 diabetes.
January 2025: Notable Drug Approvals - The Cardiology Advisor
Feb 11, 2025 · The following are some of the notable drug approvals that occurred in January 2025. Omvoh (mirikizumab-mrkz) Humanized immunoglobulin G4 monoclonal antibody that …
Researchers Quantify the Risk for Diabetes After Gestational …
May 16, 2024 · Gestational diabetes is associated with an increased risk for subsequent diabetes, according to a study published online.
Combating Medical Mistrust in the Black Community
Nov 28, 2023 · Medical mistrust causes barriers to health promotion and prevention, leading to greater health disparities in minority communities.
Association of Black Cardiologists Launches Hypertension …
Feb 12, 2024 · The Association of Black Cardiologists (ABC) is offering a Hypertension Control Program (HCP) certification for clinicians committed to preventing hypertension and improving …
Semaglutide Associated With Improved Symptoms in Obesity …
Apr 26, 2024 · Semaglutide is associated with significant improvement in HF-related symptoms and reductions in body weight in patients with obesity-related HFpEF.
Childhood Cancer Treatments May Increase Diabetes Risk
Feb 25, 2025 · Childhood cancer treatments, specifically total body irradiation, were associated with increased risk of developing diabetes among cancer survivors.
New, Noninvasive Blood Test Accurately Detects Glut1 Deficiency …
Jul 25, 2023 · A noninvasive diagnostic test for Glut1 deficiency syndrome can expedite the diagnosis and the treatment of the neurometabolic condition.
Etripamil Nasal Spray Under Review for Managing PSVT Episodes
Jul 2, 2024 · The FDA has accepted for review the New Drug Application for etripamil nasal spray for the management of paroxysmal supraventricular tachycardia.
Hospitalization, Mortality Rates in Patients With Comorbid COPD, …
Jan 7, 2022 · Patients with chronic obstructive pulmonary disease and heart failure with reduced ejection fraction may be at high risk for hospitalization and death.